Neutralizing the Threat: Pan-Ebolavirus Antibodies Close the Loop

Chad E. Mire; Thomas W. Geisbert

doi:10.1016/j.molmed.2017.06.008

Neutralizing the Threat: Pan-Ebolavirus Antibodies Close the Loop

Chad E. Mire, Thomas W. Geisbert

Microbiology And Immunology

Research output: Contribution to journal › Short survey › peer-review

8 Scopus citations

Abstract

The glycoprotein (GP) of ebolaviruses participates in a critical membrane fusion process to establish infection of a cell and therefore, represents an important target of both vaccines and antivirals. The latest reports on pan-ebolavirus monoclonal antibodies in small animal models may offer promising outcomes and insight into how best to target the GP in vaccine and antiviral discovery.

Original language	English (US)
Pages (from-to)	669-671
Number of pages	3
Journal	Trends in Molecular Medicine
Volume	23
Issue number	8
DOIs	https://doi.org/10.1016/j.molmed.2017.06.008
State	Published - Aug 2017

Keywords

Bundibugyo
Ebolavirus
Sudan
Zaire
antibody
treatment

ASJC Scopus subject areas

Molecular Medicine
Molecular Biology

Access to Document

10.1016/j.molmed.2017.06.008

Cite this

@article{5b06ed6a736e452888af9127f30b5b50,

title = "Neutralizing the Threat: Pan-Ebolavirus Antibodies Close the Loop",

abstract = "The glycoprotein (GP) of ebolaviruses participates in a critical membrane fusion process to establish infection of a cell and therefore, represents an important target of both vaccines and antivirals. The latest reports on pan-ebolavirus monoclonal antibodies in small animal models may offer promising outcomes and insight into how best to target the GP in vaccine and antiviral discovery.",

keywords = "Bundibugyo, Ebolavirus, Sudan, Zaire, antibody, treatment",

author = "Mire, {Chad E.} and Geisbert, {Thomas W.}",

note = "Publisher Copyright: {\textcopyright} 2017 Elsevier Ltd",

year = "2017",

month = aug,

doi = "10.1016/j.molmed.2017.06.008",

language = "English (US)",

volume = "23",

pages = "669--671",

journal = "Trends in Molecular Medicine",

issn = "1471-4914",

publisher = "Elsevier Ltd",

number = "8",

}

TY - JOUR

T1 - Neutralizing the Threat

T2 - Pan-Ebolavirus Antibodies Close the Loop

AU - Mire, Chad E.

AU - Geisbert, Thomas W.

PY - 2017/8

Y1 - 2017/8

N2 - The glycoprotein (GP) of ebolaviruses participates in a critical membrane fusion process to establish infection of a cell and therefore, represents an important target of both vaccines and antivirals. The latest reports on pan-ebolavirus monoclonal antibodies in small animal models may offer promising outcomes and insight into how best to target the GP in vaccine and antiviral discovery.

AB - The glycoprotein (GP) of ebolaviruses participates in a critical membrane fusion process to establish infection of a cell and therefore, represents an important target of both vaccines and antivirals. The latest reports on pan-ebolavirus monoclonal antibodies in small animal models may offer promising outcomes and insight into how best to target the GP in vaccine and antiviral discovery.

KW - Bundibugyo

KW - Ebolavirus

KW - Sudan

KW - Zaire

KW - antibody

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85022087390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85022087390&partnerID=8YFLogxK

U2 - 10.1016/j.molmed.2017.06.008

DO - 10.1016/j.molmed.2017.06.008

M3 - Short survey

C2 - 28697885

AN - SCOPUS:85022087390

SN - 1471-4914

VL - 23

SP - 669

EP - 671

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

IS - 8

ER -

Neutralizing the Threat: Pan-Ebolavirus Antibodies Close the Loop

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this